DelMar Pharmaceuticals Email Format

Pharmaceutical ManufacturingBritish Columbia, Canada2-10 Employees

DelMar Pharmaceuticals is a biopharmaceutical company focused on developing new solid-tumor cancer therapies for patients who fail or cannot tolerate current targeted or biologic treatments. Its lead program, VAL-083, is a first-in-class small-molecule chemotherapeutic that has been studied by the U.S. National Cancer Institute and is approved in China for lung cancer and chronic myeloid leukemia. The company is conducting U.S. clinical trials of VAL-083 for refractory glioblastoma multiforme and is based in Vancouver, British Columbia.

VAL-083 is associated with a novel mechanism of action and may have activity across a range of solid tumors, including glioblastoma and non-small cell lung cancer, according to published data. DelMar focuses on patient populations with limited options due to resistance or intolerance to existing therapies, pursuing development in the U.S. for difficult-to-treat cancers.

Sign up for free to view info

Company overview Employee directory